Brepocitinib Controls Skin Disease in Dermatomyositis

◆ ◆ The Wire takeaway

You have a chance to offer patients with dermatomyositis a targeted oral therapy that controls skin symptoms faster and more effectively than existing treatments. This opens new routes for drug positioning in autoimmune skin conditions where rapid symptom relief is critical.